Skip to content

AARD AARD Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$160M+583%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$0-100%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$1K
Viking Therapeutics logo
Viking TherapeuticsVKTX
$450K+28.9%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$23.37M+96.1%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$0-100%

Other financials

Income statement

See full
Revenue-
Operating income-$22.5M-115%
Net income-$21.6M-132%
EPS (diluted)-$0.99-39.4%

Balance sheet

See full
Cash & equivalents$62.4M+136%
Total debt$336.0K-53.7%
Total equity$87.0M-42.3%
Total assets$98.6M-37.2%

Cash flow

See full
Operating cash flow-$18.9M-65.7%
CapEx--100%
Free cash flow-$16.8M-117%

Valuation

See full
Market cap$124.35M-58.6%
Enterprise value$62.25M-77.4%

Returns & leverage

See full
Return on equity-58.8%
Debt / equity0.0×
Current ratio8.1×-17.8×

Where this comes from

Reported directly by AARD in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: AARD’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about AARD's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AARD's stock issuance proceeds?
AARD (AARD) reported stock issuance proceeds of $4K in Q1 2026.
How has AARD's stock issuance proceeds changed year-over-year?
AARD's stock issuance proceeds decreased by 96.4% year-over-year, from $110K to $4K.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.